Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia.

We recommend the use of TA in ITP patients with bleeding and/or an increased bleeding risk. Ultimately, cessation of bleeding plays a key role in the management of such affected patients. However, future studies are required to optimize dose and administration routes (intravenous or oral).